Venture Market News for October 9, 2018
- Kraig Biocraft Laboratories prepares for shipment of recombinant spider silk silkworm eggs to Vietnam
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it is finalizing the details of its first shipment of the Company’s proprietary recombinant spider silk silkworm eggs to Vietnam. The Company is coordinating the details of this shipment with senior officials within key central Vietnamese government ministries, as well as senior leadership within Quang Nam province.
- CV Sciences, Inc.’s PlusCBD Oil™ featured on Oct. 3rd Episode of ‘The Dr. Oz Show’
PlusCBD Oil™ Capsules featured as one of the industry-leading in efficacy and strength; Dr. Oz segment cites sales of CBD products expected to increase 700% over the next year
LAS VEGAS, Oct. 09, 2018 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), preeminent supplier and manufacturer of hemp-derived phytocannabinoids including industry leading brand, PlusCBD Oil™, today announced its feature on the Oct. 3rd episode of ‘The Dr. Oz Show.’
- Adipose Stem Cells Demonstrate Effectiveness in Repairing Decubitus Ulcers
Paper Published by USRM Chief Science Officer in Journal of Medical Cases
SUNRISE, Fla., Oct. 9, 2018 /PRNewswire/ — U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully used autologous stem cells from fat tissue to repair decubitus ulcers.
- Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
BEVERLY, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that it has secured new financing for up to $10 million from one multi-family office focused on healthcare and life sciences, including an initial net placement of approximately $2.2 million over the first 30 days. These funds will be used to continue to advance the Company’s pipeline of first-in-class drug candidates: Brilacidin for Oral Mucositis, Kevetrin for Ovarian Cancer and Prurisol for Psoriasis.
- Namaste Provides Official Response to Recent Publications
VANCOUVER, Oct. 9, 2018 /CNW/ – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is aware of several misleading and false “research reports” published by Citron Research Inc. (“Citron”) and press releases and advertisements distributed by several US-based law firms seeking plaintiffs for potential securities litigation against the Company.
- RYU Apparel Inc. Prevails in Trade-mark Legal Matter with Lululemon Over RYU Mark
VANCOUVER, Oct. 9, 2018 /CNW/ – RYU Apparel Inc. (TSXV: RYU) (OTCQB: RYPPF) (“RYU” or the “Company”), creator of urban athletic apparel, is pleased to announce that it has successfully protected its registration over its RYU trade-mark registrations in Canada, including the RYU logo. The Company also has trade-mark registrations in the United States, China and Hong Kong.
- MGX Signs Definitive Agreement to Acquire Lithium Brine Projects in Chile – Permitting in Place to Commence Drill Program
VANCOUVER, BC / ACCESSWIRE / October 9, 2018 / MGX Minerals Inc. (“MGX” or the “Company”) (OTCQB: MGXMF) (CSE: XMG) (FRA: 1MG) is pleased to announce it has signed the Definitive Option Agreement, after completing the due diligence in relation to the Memorandum of Understanding dated August 8th 2018, to acquire 50% of the issued shares of Chilean Lithium Salars SpA (“CLS”). CLS is a wholly owned subsidiary of Chilean Lithium Salars Pty Ltd. (“CLSH”) and holds a 100% interest in three prospective lithium exploration Projects (the “Projects”) located in Chile, including Francisco Basin, Laguna Brava and Laguna Escondida Lithium Projects.
- Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum
Company Further Develops Its Autistic Spectrum Disorder (ASD) Drug Technology and Expects Several Development Partnerships In Anticipation of Clinical Program in 2019
NEW YORK, October 9, 2018 /PRNewswire/ –Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to provide an update on QBM001, its Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children.
- United Cannabis Corporation Gives Guidance on Third Quarter Results
Company To Report $2 Million In Revenue For The Third Quarter, Forecasting $10 Million For the Year
DENVER, CO / ACCESSWIRE / October 9, 2018 / United Cannabis Corporation (OTCQB: CNAB) (the “Company” or “United Cannabis”) today provided preliminary, unaudited figures on revenues for the third quarter 2018 and offered guidance for the year.
- Medical Marijuana, Inc. Announces Q3 2018 as the Largest Sales Bookings Quarter in Company History
SAN DIEGO, Oct. 9, 2018 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the company and its subsidiary Kannaway® have booked their largest-ever sales revenue quarter in their history in Q3 2018, as well as reached major milestones in their business operations.
- eWellness Expands Sales Funnel To Include the U.S. Auto Industry
Culver City, CA, Oct. 09, 2018 (GLOBE NEWSWIRE) — eWellness Healthcare Corporation – (OTCQB: EWLL) – a provider of the state of the art PHZIO platform for the physical therapy (PT) and telehealth markets, announced today that the Company now plans to expand its Sales Funnel to include the U.S. Auto Industry that collectively has approximately 7.25 million employees, on PT Telehealth and TeleRehab related to Worker Compensation that breakdown as follows:
Connect with 24/7 Market News on social media:
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.
24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. 24/7MN owns KBLB shares that it can sell at any time. 24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
For further information on 24/7 Market News, please go to www.247marketnews.com
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements
24/7 Market News